Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
National Health Research Institutes has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 6 examiners and 6 art units, giving every pending action a distinct examination setting. This breadth makes portfolio-level coordination important, particularly for maintaining consistent scientific terminology and support across separate responses.
ARMATO JR, DENNIS IGNATIUS is the busiest examiner, with 1 pending matter. The profile shows no concentration with a single examiner, so counsel's review should prioritize cross-matter consistency while preserving application-specific arguments for each art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (50%) |
| §103 only | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| VASSELL, MEREDITH ABBOTT | 1 | 29.9% | +45.8% |
| BALLARD, KIMBERLY | 1 | 53.6% | +49.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710913 | Anti-HSP90 alpha antibody and uses thereof | GUSTILO, ESTELLA M | — |
| 18543232 | METHOD FOR SELECTING A DRUG CANDIDATE FOR TREATING OR PREVENTING OR DELAYING THE ONSET OR PROGRESSION OF AN AMYLOIDOGENIC DISEASE | STEELE, AMBER D | — |
| 18453435 | METHOD AND SYSTEM FOR ESTABLISHING DISEASE PREDICTION MODEL | VASSELL, MEREDITH ABBOTT | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18374326 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES | VALLE, ERNESTO | 34d |
| 18667786 | Microfluidic chip and use thereof for continuous monitoring of bacterium intended for motion, growth and morphology detection | ARMATO JR, DENNIS IGNATIUS | — |
| 18710913 | Anti-HSP90 alpha antibody and uses thereof | GUSTILO, ESTELLA M | — |
| 18453435 | METHOD AND SYSTEM FOR ESTABLISHING DISEASE PREDICTION MODEL | VASSELL, MEREDITH ABBOTT | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1646 | 1 |
| 1658 | 1 |
| 1623 | 1 |
| 1687 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667786 | Microfluidic chip and use thereof for continuous monitoring of bacterium intended for motion, growth and morphology detection | ARMATO JR, DENNIS IGNATIUS | 1651 | §103 | Final Rejection | — | Pending | May 17, 2024 |
| 18710913 | Anti-HSP90 alpha antibody and uses thereof | GUSTILO, ESTELLA M | 1646 | §102§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18543232 | METHOD FOR SELECTING A DRUG CANDIDATE FOR TREATING OR PREVENTING OR DELAYING THE ONSET OR PROGRESSION OF AN AMYLOIDOGENIC DISEASE | STEELE, AMBER D | 1658 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18374326 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES | VALLE, ERNESTO | 1623 | §103 | Final Rejection | 34d | Pending | Sep 28, 2023 |
| 18453435 | METHOD AND SYSTEM FOR ESTABLISHING DISEASE PREDICTION MODEL | VASSELL, MEREDITH ABBOTT | 1687 | §101§103§112 | Non-Final OA | — | Pending | Aug 22, 2023 |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | 1675 | §101§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational Health Research Institutes has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Dennis Ignatius Armato Jr. has the most, with 1 of National Health Research Institutes's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
